Phase 1 Start~month

Phase 1 Start: First-In-Human, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy

GMAB overview →Track this catalyst
Indication
Solid Tumours

Other upcoming events for GMAB

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Ri
Phase 3 ReadoutPhase 3 Topline: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Rela
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investig
Phase 3 ReadoutPhase 3 Topline: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Rela
Phase 3 ReadoutPhase 3 Topline: A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pe

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

  • 200 free AI credits / month to run live multi-agent analysis
  • Watchlist, catalyst alerts & the biotech event calendar
  • Full pipeline, financials & FDA data on every company
Start Free
    Phase 1 Start: First-In-Human, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy — GMAB Phase 1 Start | BioSniper